Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
US-2024335536-A1 · Oct 10, 2024 · US
Mafb mutants and uses thereof
US2016304584A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016304584-A1 |
| Application number | US-201415101425-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 3, 2014 |
| Priority date | Dec 3, 2013 |
| Publication date | Oct 20, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to MafB mutants and uses thereof for research, screening and therapeutic purposes. In particular, the present invention relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the glutaminic acid residue at position 269 has been deleted or substituted with a basic amino acid. The present invention also relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the valine residue at position 277 has been deleted or substituted with a polar amino acid.
First claim
Opening claim text (preview).
1 . A MafB mutant polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 1 or 2, or a function conservative variant thereof, wherein a glutamic acid residue at position 269 has been deleted or substituted with a basic amino acid, and/or wherein a valine residue at position 277 has been deleted or substituted with a polar amino acid. 2 . The MafB mutant polypeptide of claim 1 wherein the basic amino acid is selected from the group consisting of arginine,…
Assignees
Inventors
Classifications
- C07K14/82Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016304584A1 cover?
- The present invention relates to MafB mutants and uses thereof for research, screening and therapeutic purposes. In particular, the present invention relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the glutaminic acid residue at position 269 has been deleted or substituted with a basic amino acid. …
- Who is the assignee on this patent?
- Inserm (Institut Nat De La Santé Et De La Rech Médicale, European Molecular Biology Laboratory, Centre Nat De La Rech Scient (Cnrs), and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/82. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Oct 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).